Clinical trial NCT04570527: Optimized Cardioprotection Therapy in Obese Subjects With CAD
Official title: Effects and Mechanism of Adipokines Cardiac Protection in Obese Patients With Coronary Artery Disease (CAD)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Obesity
Adiposis; Heart
Keywords: Coronary artery disease
Adipokines
Obesity
Diabetes mellitus
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2020-09-30
Enrollment: 200
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients of CAD were enrolled in this study

Brief summary: The purpose of this study is to investigate the efficacy and mechanism of Adipokines Cardiac Protection in Obese Patients With coronary artery disease (CAD).

Detailed description: Adipokines (or adipocytokines) can be defined as a group of more than 600 bioactive molecules made from adipose tissue that acts as paracrine and endocrine hormones. Adipokines are involved in maintaining varieties of processes such as, appetite and satiety, energy expenditure activity, endothelial function, blood pressure, hemostasis, adipogenesis, insulin sensitivity, energy metabolism in insulin-sensitive tissues, fat distribution and insulin secretion in pancreatic β-cells. Adipokines may contribute to reduce scar formation and improve cardiac function in coronary artery disease (CAD). Reperfusion therapy such as percutaneous coronary intervention (PCI) should be administered to all eligible patients with CAD symptom. However, our previous work showed that obese patients may benefit more from PCI. Thus, the aim of the present study was to investigate the efficacy and mechanism of adipokines cardiac protection for obese and non-obese patients with coronary artery disease (CAD).

Eligibility criteria: Inclusion Criteria:

coronary artery disease according to the WHO definition With or without percutaneous coronary intervention

Exclusion Criteria:

previous Coronary artery bypass grafting (CABG) cardiomyopathy atrial fibrillation or flutter previous heart surgery severe valvular heart disease disease of the hematopoietic system NYHA functional class IV heart failure at baseline severe renal, lung and liver disease cancer

Primary outcomes:
measure: Number of patient death during the follow up period
timeFrame: 1 year
Secondary outcomes:
measure: Left ventricular ejection fraction
timeFrame: 1 year
measure: Number of target vessel revascularization
timeFrame: 1 year
measure: Angina class according to the canadian cardiovascular society (CCS) classification
timeFrame: 1 year
measure: Scores on the Seattle angina questionnaire
timeFrame: 1 year
measure: six-min walk distance (6MWD)
timeFrame: 1 year
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing hospital
state: Shaanxi
Study officials:
affiliation: Xijing Hospital
name: Dongdong Sun, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: